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Background: In 2012, the levels of chlamydia control activities including primary prevention, effective case
management with partner management and surveillance were assessed in 2012 across countries in the
European Union and European Economic Area (EU/EEA), on initiative of the European Centre for Disease
Control (ECDC) survey, and the findings were compared with those from a similar survey in 2007. Methods:
Experts in the 30 EU/EEA countries were invited to respond to an online questionnaire; 28 countries responded,
of which 25 participated in both the 2007 and 2012 surveys. Analyses focused on 13 indicators of chlamydia
prevention and control activities; countries were assigned to one of five categories of chlamydia control.
Results: In 2012, more countries than in 2007 reported availability of national chlamydia case management
guidelines (80% vs. 68%), opportunistic chlamydia testing (68% vs. 44%) and consistent use of nucleic acid amp-
lification tests (64% vs. 36%). The number of countries reporting having a national sexually transmitted infection
control strategy or a surveillance system for chlamydia did not change notably. In 2012, most countries (18/25,
72%) had implemented primary prevention activities and case management guidelines addressing partner
management, compared with 44% (11/25) of countries in 2007. Conclusion: Overall, chlamydia control activities
in EU/EEA countries strengthened between 2007 and 2012. Several countries still need to develop essential
chlamydia control activities, whereas others may strengthen implementation and monitoring of existing activities.
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Introduction
Chlamydia is the most commonly reported infection in the European
Union and the European Economic Area (EU/EEA).1 Untreated,
chlamydia infections can cause complications, including pelvic in-
flammatory disease, which may lead to ectopic pregnancy or tubal
factor infertility in women, and epididymitis in men.2,3 The imple-
mentation of chlamydia control activities influences who is tested and
how many cases are detected and reported.4 Surveillance data from
EU/EEA Member States, collected in The European Surveillance
System (TESSy, ECDC), show that the number of cases reported
has increased over time and varies widely between countries
(from <1 to 600 per 100 000 population in 2012).5 Countries across
Europe differ in the priority they give to the control of sexually
transmitted infections (STI) such as Chlamydia trachomatis
(chlamydia) and in their level of implementation of primary
prevention, STI services and surveillance data collection.6,7
The ECDC first assessed activities aimed at the control of chlamydia
infections in EU/EEA Member States in 2007.6,7 Survey responses were
used to define categories of chlamydia control, according to the level
of infrastructure required to implement the activities, and to allocate
each country to a category. ECDC used the survey findings to publish
a guidance document in 2009 that aimed to support countries to
strengthen their national control strategies. The guidance document
suggested a step-by-step approach to chlamydia control,8 with
essential activities, policies and evaluation indicators.
In 2012, ECDC conducted a second survey of chlamydia control
activities in EU/EAA Member States. The objectives were: to assess
the organization and implementation of chlamydia control activities,
including primary prevention; and to examine changes between
2007 and 2012.
Methods
The survey methods are described in full in a technical report.9
ECDC invited national STI surveillance contacts from EU/EEA
Member States to respond to an online questionnaire between
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December 2012 and February 2013. The questionnaire included
63 questions in six sections: (i) guidelines on chlamydia case
management and testing; (ii) laboratory diagnosis; (iii) strategies,
plans and organization of STI healthcare; (iv) strategies and
activities for primary prevention; (v) surveillance and (vi) oppor-
tunistic testing and screening programmes.9 The 2012 questionnaire
was adapted to use an online survey tool (Sharepoint, Microsoft);
most questions were similar to the 2007 survey (Microsoft Word,
sent electronically). Questions about primary prevention were new.
Respondents were also invited to indicate the level of chlamydia
control that described the situation in their country, based on the
levels described in the ECDC guidance (A to D, explained below)
and comment on chlamydia control activities. The survey included
questions to evaluate the use of the guidance document which have
been analysed and will be reported separately.10
The survey team developed a set of 13 ‘key indicators’ of
chlamydia prevention and control activities (Supplementary table
S1), based on the questionnaire sections and the ECDC guidance
document.8 Data for 2012 were collated and merged with responses
from 2007. The findings per key indicator were described for 2012
and responses compared between 2007 and 2012 for questions asked
and for countries taking part in both surveys.
Survey responses in 2012 were then used to determine a country’s
category of control activities. Two investigators independently
assigned each Member State to a category, using the same method
as in the 2007 survey.7 In cases of discordant classification the
investigators reached a consensus by discussion or, if necessary, a
third reviewer adjudicated. The five categories are shown in table 1.
The numbers of countries in each category in 2007 and 2012 were
compared.
The assigned category (1–5) for each country in 2012 was mapped
to the respondent’s self-assessed level (A to D) because future
assessments of chlamydia prevention and control activities will be
based on criteria in published ECDC guidance. The survey categories
and levels in the 2009 guidance partly overlap, as shown in table 1.
Level A describes activities for the primary prevention of STI but no
other organized chlamydia control activities; category 1 does not
mention prevention because the 2007 survey did not include this
topic; level B covers categories 2 and 3, requiring clinical chlamydia
guidelines either or not include partner notification; level C and D
and category 4 and 5 are the same.
Secondary data [population size, per capita gross domestic
product (GDP)11] and rates of chlamydia cases reported to ECDC
in 20115 were also recorded. Information about the completeness of
chlamydia surveillance (this survey and ECDC report5) was used to
estimate the number of cases per 100 000 for each country with
complete reporting. These estimated rates were compared to the
assigned category of control activities. All analyses were done with
SPSS Statistics (version 19.0, IBM, New York).
Results
Twenty-eight of 30 (93%) EU/EEA Member States responded to the
survey in 2012; Greece and Poland did not respond. Luxembourg
reported that chlamydia control had not changed, so responses from
2007 were used. For 25 countries data were available from both
surveys (Slovakia, Cyprus, Czech Republic had no data for 2007).
National strategies for sexual health promotion and
STI control (key indicator 1–3)
A total of 16/27 (59%) countries reported a national sexual health
promotion strategy in 2012 (no information available from
Luxembourg). Most countries (22/27; 81%) reported at least one
organized activity to improve knowledge, behaviour or awareness
of chlamydia including regular media campaigns (6/22), social
media campaigns (13/22), sexual health education as standard
(11/22) or voluntary (7/22) part of school curricula. Eleven of 28
countries (39%) reported a national strategy/plan for STI control;
six explicitly included chlamydia control (figure 1). Among
countries participating in both surveys, 8/25 (32%) reported
national STI control strategies in 2007 compared with 10/25
(40%) in 2012. In addition, Sweden and Denmark revised their
strategies; both reported a shift in priorities towards primary
prevention of STI.
Health services for STI care (key indicator 8)
Dedicated health services offering diagnosis and treatment for
people with STI were available in 25/28 (89%) countries in
specialized or general healthcare facilities. Liechtenstein,
Luxembourg and Slovakia reported no public dedicated STI
services. Availability of services for STI care was similar in 2007
(22/25 countries; 88%) and 2012 (23/25; 92%). Listed among the
three most common providers of STI care per country were: gynae-
cologists (25/28, 89%), STI/GUM/dermatovenereology clinics
(23/25, 82%), urologists (18/28, 64%), family planning or contra-
ception clinics (14/28, 50%) and general practitioners (12/28, 43%).
Belgium included hospital services for infectious diseases and
Sweden mentioned a medical service for ordering homesampling
tests via the Internet as one of the top three providers.
In 11 of 28 countries (39%), the costs of consultation, diagnosis,
treatment and partner notification within STI care were fully covered
or reimbursed by national health insurance; in 5 countries (18%)
costs were partially covered, in 10 countries (36%) only some were
(partially) covered, whereas in 2 countries none was covered. Costs of
consultation and diagnosis were more often covered than costs of
treatment or partner notification. In 2012, costs were completely
covered in 10/25 countries (40%) compared with 8/25 (32%) in 2007.
Diagnostic tests for C. trachomatis detection (key
indicator 9–10)
Nucleic acid amplification tests (NAAT) to detect C. trachomatis were
available in all countries that participated in 2012. In 22 countries
NAAT was the most common diagnostic method in the public sector;
in five countries other diagnostic methods were still more common:
direct immunofluorescence microscopy (Cyprus, Hungary, Romania),
enzyme-linked immunosorbent assay (Bulgaria, Portugal) and
chlamydia culture (Romania). Seventeen of 28 countries (61%)
reported that NAAT was used for >90% of samples tested. In 2007,
9 (36%) and in 2012, 16 (64%) of 25 countries taking part in both
surveys used NAAT in >90% of tests.
Questions on further testing capacity for chlamydia were
answered by 22 countries: 18 (82%) had laboratory capacity to
detect C. trachomatis variants that might not be detected by
routine NAATs (such as the new variant described in Sweden12),
19 (86%) had capacity to detect L-genotypes causing
Lymphogranuloma venereum and eight countries could assess
C. trachomatis antimicrobial susceptibility.
Case management guidelines (key indicator 4, 6)
In 2012, 22/28 (79%) countries had at least one national guideline
that covered chlamydia diagnosis and treatment for one or more
medical professions; in total 68 guidelines were reported. Nineteen
countries (68%) had guidelines for all healthcare practitioners, all
with additional specialist guidelines except Estonia. In 17 countries
one or more guidelines were new or updated since the last survey.
There were more guidelines in 2012 (62 guidelines in 20/25
countries; 80%) than in 2007 (25 guidelines in 17/25; 68%).
Partner notification
Case management guidelines explicitly addressed case finding
through partner notification in 19/28 (68%) countries in 2012. In
nine countries guidelines recommended patient referral; in seven
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countries, recommended partner notification practices included
(also) provider referral (five countries), patient delivered partner
therapy (three countries) or a choice between patient/provider
referral depending on the situation (one country).
Opportunistic testing for chlamydia
In 18/28 (64%) countries, case management guidelines recom-
mended opportunistic chlamydia testing for one or more specific
groups of asymptomatic people; three country respondents stated
that opportunistic testing was implemented routinely; 12 indicated
limited/infrequent implementation and three reported recommen-
dations were not implemented. Target groups for testing included
young people (10/18; when specified this was <25 years except in
France where the age group was 15–30 years), pregnant women
(10/18) and other high risk groups, such as those practising sex
without a condom (1/18), after partner change (3/18) or men who
have sex with men (6/18). Respondents also specified clinical indi-
cations: notified partners or before gynaecological procedures. In
2012, the number of countries with opportunistic testing in
guideline(s) (17/25; 68%) was higher than in 2007 (11/25; 44%).
Repeated testing
Case management guidelines recommended repeated testing after
positive chlamydia tests in 14 countries: to confirm a positive test
(two countries); as a test of cure, typically 3–6 weeks after diagnosis,
for all cases (six countries) or specific cases (four countries) such as
suspected poor compliance, persistent symptoms or non-standard
treatment; or testing for reinfection, several months after infection
(seven countries). Annual repeated screening was recommended in
four countries.
Chlamydiascreening programmes (key indicator 7)
For this survey, a chlamydia screening programme was defined as a
continuing organized service that screens a high enough proportion of
the target population at regular intervals to achieve defined targets,
while minimizing harm.9,13 One country (England, UK) reported
a screening programme based on opportunistic testing.
The Netherlands stopped a pilot of a population-based screening
programme in 2012. Germany reported reimbursement of
chlamydia screening tests for young women since 2008, which fulfils
the national definition of a screening programme; this activity corres-
ponds to our definition of opportunistic testing. In 2012, fewer
countries had (plans for) organized chlamydia screening
programmes (4/25, 16%) than in 2007 (11/25; 44%). Of the three
countries with plans in 2012, France and Luxembourg also reported
this intention in 2007, whereas Malta’s plan was new. There were plans
to introduce or pilot an organized chlamydia screening programme
in three other countries in 2007, but these were not reported in 2012.
Surveillance (key indicator 11–13)
A national surveillance system to report and monitor diagnosed
chlamydia infections was in place in 25/28 (89%) countries.
Austria and Portugal reported no national chlamydia surveillance
system and Spain informed about plans to introduce a system in
2013. In 19/25 (76%) countries with a surveillance system, reporting
from all settings was compulsory (comprehensive mandatory
reporting, table 2). In six countries, reporting was done in selected
sentinel settings. The reported types of surveillance systems were
similar in 2007 (22/25; 88%) and 2012 (23/25; 92%).
Nine of the 25 countries (36%) indicated their data collection was
complete and covered (nearly) all cases detected annually (table 2).
Reasons for partial coverage were: organizational, i.e. sentinel sur-
veillance; voluntary laboratory reporting and under-reporting by STI
health care providers. Under-reporting of cases was the main reasonT
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given by countries with low rates of reported chlamydia. Surveillance
data included numbers of chlamydia tests in 9/25 (36%) countries.
Ten of 28 countries collected data on clinical complications
caused by chlamydia. Seven countries collected data on Pelvic
Inflammatory Disease (PID), five on ectopic pregnancy, three on
infertility and two on epididymitis.
Level of chlamydia control activities
Nineteen of 28 (68%) countries had activities in categories 3–5
(table 1 and figure 2), an increase since the previous survey: for
the 25 countries participating in both surveys, 18 (72%) in 2012
and 11 (44%) in 2007 were in categories 3–5. Twenty-seven
countries completed the self-assessment of the level of chlamydia
control. Three countries (3/27; 15%) reported that they did not
think they fitted into any of the levels described. The remainder
classified their country as level A, 6/27 (22%); level B, 9/27 (33%);
level C, 7/27 (26%); level D, 2/27 (7%). Comparing the self-
assessment to the categories assigned by the survey team (table 1),
six countries assigned themselves to a level with less intensive
activities than assigned by the survey team, while four countries
selected a level with more intensive activities.
There was no statistical evidence for a difference between mean
GDP per capita in 2012 of countries classified in five categories or
regrouped in two categories (category 1 and 2 vs. category 3 or
higher). The assigned category of chlamydia control was not clearly
related to the type of surveillance system, but appeared to be
related to the estimated reporting rate (table 2). Seven countries
(all in categories 4 or 5, Denmark, Finland, Iceland, Netherlands,
Norway, Sweden and UK) reported more than 90% of chlamydia
cases recorded by ECDC in 2011, but comprise only 23% of the
EU/EEA population. These countries implement recommendations
for opportunistic chlamydia testing and (except Netherlands) sur-
veillance systems with comprehensive coverage. Five countries,
Czech Republic, France, Germany, Liechtenstein and Portugal,
(37% EU/EEA population) did not contribute data to ECDC case
reports in 2011. Case reporting rates were low in most Eastern (e.g.
Bulgaria, Hungary, Romania) and southern (Cyprus, Italy, Malta and
Spain) European countries despite mandatory reporting systems
in most of them; their level of chlamydia control ranged widely.
Discussion
A comparison of two cross-sectional surveys found that, in 2012
more EU/EEA Member States than in 2007 reported organized
chlamydia control activities. The number of countries with
national chlamydia case management guidelines also increased.
Compared with 2007, the availability of dedicated health services
for STI care was generally maintained. More than half of EU/EEA
Figure 1 EU/EEA countries with a national strategy or plan about STI control in 2012. CT= chlamydia. UK situation based on England.
Adapted from ECDC Report7
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Member States reported a national sexual health promotion strategy
in 2012 but most had no documented STI control strategy. A sig-
nificant progress was the increase in the consistent use of NAAT
indicating increased accuracy of laboratory diagnoses; on the other
hand, only four countries insured that all laboratories participated in
an international quality assurance scheme. The surveillance of
diagnosed cases has not changed since 2007.
The 2012 survey of chlamydia control had a high response rate
that allowed a good comparison with the 2007 survey. There were
two main limitations to the survey format. First, the questionnaire
covered a variety of different specialist topics and one person often
responded to all questions. Respondents might have misunderstood
or misinterpreted some questions, although they were encouraged to
consult others and could refer to a glossary of definitions. In
addition, a single response for a whole country might not describe
regional variations accurately, particularly in larger countries or
where healthcare services are devolved. Second, the change of
survey format between 2007 and 2012 and re-wording of some
questions might have affected their comparability. To address this
problem, we asked respondents for clarification if responses to the
two surveys were contradictory.
EU/EEA Member States with more intense chlamydia control
activities and more complete reporting to surveillance systems
reported higher rates of diagnosed cases to TESSy.5 This finding,
across a large geographic region, supports ecological studies in
single countries that show that high rates of chlamydia cases
reported in surveillance systems reflect more the coverage of
testing14 and not the comparative incidence or prevalence of
chlamydia. Estimates of chlamydia prevalence in countries with
nationally representative surveys3,15 show similar conclusions, and
suggest that many asymptomatic chlamydia infections are neither
diagnosed nor reported in countries with low case reporting rates.
The number of EU/EEA Member States with national guidelines
for chlamydia case management that include partner notification,
increased between 2007 and 2012. However, the existence of recom-
mendations does not necessarily mean that they are implemented;
indeed STI experts in several countries remarked that they were
unsure about the level and consistency of implementation. In
2012, more EU/EEA countries than in 2007 reported that
guidelines recommend opportunistic testing, but only three
indicated that it was implemented in routine practice.
Future assessments of chlamydia prevention and control can use
the self-assessed levels (A to D) developed for the 2009 ECDC
Guidance document on chlamydia control. The level for each
country has been mapped to the previously assigned categories;
discrepancies were minor and reflected the difference between
what is described in guidelines and respondents’ statements about
actual practices.
Figure 2 Map of Europe indicating the level of chlamydia control based on the countries’ accomplishments of key indicators assessed in the
survey in 2012. UK situation based on England. Adapted from ECDC Report7
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Reported chlamydia screening policies changed between 2007 and
2012. The fall in the proportion of countries with an ongoing or
planned chlamydia screening programme could partly reflect uncer-
tainty about the balance between benefits and harms of organized
screening programmes.13 This change may also reflect changes in
economic circumstances across Europe during the period between
the surveys. In the Netherlands, the pilot programme of register-
based chlamydia screening (reported in 2007) was discontinued in
2012 after a controlled trial showed limited uptake and no change in
chlamydia test positivity after three rounds of screening.16 In
England, opportunistic chlamydia screening has continued.17
Population-based estimates of chlamydia prevalence in 1999–2000
(before the programme started) and 2010–2012 were similar,
however.18 No other European countries have done analyses
showing if screening would be effective, except in Ireland where a
modelling study concluded that an opportunistic chlamydia
screening programme would be expensive to implement nationally
and is unlikely to be judged cost-effective by policy makers.19 More
insight in trends and determinants of chlamydia-associated compli-
cations is necessary. Sweden and Denmark, which have widespread
opportunistic chlamydia screening, but no organized programme,
reported that their STI control strategies had shifted from
promoting testing to intensifying primary prevention activities.
The findings of this survey have implications for policy making,
service provision and evaluation of chlamydia prevention and
control. Most EU/EEA Member States still did not have a written
STI control strategy in 2012. Despite the presence of dedicated
services for STI control in most countries, treatment for
chlamydia is provided free in less than half. Given the equipoise
about the efficacy of organized chlamydia screening and the
complex infrastructure required for its implementation, efforts
should focus on ensuring implementation of the essential elements
of STI control; primary prevention, comprehensive case
management and surveillance. The 2012 survey identified a
number of countries that still need to develop national sexual
health promotion strategies and case management guidelines
including partner notification. For countries already reporting
these achievements, the next steps will be to improve their imple-
mentation and monitor the quality of care, so that recommendations
on paper are aligned with daily practice. Overall, reported activities
for chlamydia prevention and control in Europe strengthened
between 2007 and 2012.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 Chlamydia is the most commonly reported STI in European
countries.
 The variation in chlamydia case reporting rates between
countries across Europe reflects differences in the implemen-
tation of chlamydia control activities and surveillance.
 Chlamydia control has strengthened in Europe in recent
years, but differences between countries remain large.
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